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Introduction. Gamma Knife radiosurgery (GK-SRS) is commonly used to treat cerebral metastases. Although additional
intracranial metastases are often found on the day of GK-SRS, the signiﬁcance of ﬁnding them is unknown. Methods.A
retrospective review of 133 patients undergoing GK-SRS for cerebral metastases was performed. The change in number of
metastases detected between initial referral magnetic resonance imaging (MRI) and subsequent treatment MRI was quantiﬁed.
Multivariate and Kaplan-Meier analyses were employed to examine the signiﬁcance of identifying additional lesions. Results.
Additional lesions were identiﬁed in 41% of patients. An increasing number of metastases on referral MRI (P = 0.001) and the
presence of progressive systemic disease (P = 0.003) were predictive of identifying additional metastases. Median survival was 6.9
months for patients with additional metastases, compared to 12.1 months for patients without additional metastases (hazard ratio
1.56,P = 0.021).Conclusions.Identifyingadditionalmetastases onthedayofGK-SRSmayaddimportantprognosticinformation.
1.Introduction
Approximately 15–40% of cancer patients will develop
metastatic lesions to the brain [1, 2]. Indeed, metastatic
intracranial disease is 10-fold more common than primary
brain tumors [3]. The presence of metastatic intracranial
disease is still uniformly considered to be a poor prognostic
indicator [4]. In the oncology literature, the treatment of
cerebral metastases with whole-brain radiotherapy (WBRT)
and/or Gamma Knife radiosurgery (GK-SRS) has not
signiﬁcantly changed overall survival [4]. However, more
recent radiosurgical studies suggest that some patients with
intracranial metastases are surviving longer (≥4y e a r s )[ 5,
6]. Nonetheless, very few factors have been reproducibly
identiﬁed as predictive of outcome. Strategies to further
improve survival may rest on the accurate identiﬁcation of
novel prognostic factors.
Additional intracranial metastases are often identiﬁed
on the day of GK-SRS [7]. However, little is known
about the prognostic signiﬁcance of identifying additional
cerebral metastases during GK-SRS. To understand this
relationship, we retrospectively analyzed data from a cohort
of patients who underwent GK-SRS for cerebral metastases,
to determine which factors were predictive of identifying
additional cerebral metastases and whether the identiﬁcation
of additional cerebral metastases had an eﬀect on survival.
2.MaterialsandMethods
2.1. Study Population. We performed an Institutional-
Review-Board-approved retrospective review of medical
recordsatYale-NewHavenHospitalandtheYale-NewHaven
Gamma Knife Center for all patients who underwent their
ﬁrst GK-SRS treatment for intracranial metastases between
May 1, 2002 and March 30, 2006. All patients gave their
informed consent prior to inclusion in the study.
All patients were referred accompanied by diagnostic
1.5Tesla gadolinium-enhanced axial magnetic resonance
images (MRI); imaging parameters were otherwise het-
erogeneous. The number of pre-GK-SRS metastases was
determined based on these referral scans. On the day of2 International Journal of Surgical Oncology
GK-SRS, all patients underwent gadolinium-enhanced axial
MRI on a 1.5Tesla magnet with a 3-dimensional spoiled
gradient recalled acquisition sequence using 2mm cuts with
no gap. All GK-SRS procedures were performed on a model
C Leksell Gamma Knife (Elekta Instruments). All identiﬁed
metastases were treated. The GK-SRS dose delivered to the
tumormarginrangedfrom18to24Gy,prescribedtothe40–
70% isodose line. All patients who underwent GK-SRS had a
Karnofsky Performance Score ≥70.
We collected data on demographics (age, sex), primary
disease (pathology, systemic control at the time of GK-SRS),
chemotherapy, cranial surgery, time between diagnostic and
treatment scans, WBRT, and number of metastases (pre-
GK-SRS and GK-SRS). Systemic control was deﬁned as no
detectable progression of primary tumor in organ systems
outside of the central nervous system, at the time of GK-
SRS.WeaccessedtheConnecticut TumorRegistryandSocial
Security Administration Death Master File to obtain dates of
all patient deaths that occurred by July 1, 2008.
2.2. Data Analysis. Statistical analyses were performed using
STATA programming software (version 9.0, StataCorp LP,
College Station, TX, USA). The primary endpoint was the
changeinnumberofmetastasesdetectedbetweenthereferral
diagnostic pre-GK-SRS MRI and the subsequent treatment
MRI(“Delta Mets”). Thepredictor variables thatwereexam-
ined included age, sex, primary pathology, systemic control,
chemotherapy, cranial surgery, time between diagnostic and
treatment scans, WBRT, and number of metastases (both
pre-GK-SRS and at GK-SRS).
Means,standarddeviations,andmedianswerecalculated
for categorical variables. The 10th, 25th, 50th, 75th, and
90th percentiles were calculated for continuous variables.
For subgroup analyses, we used the Fisher exact test for
categorical variables and the Wilcoxon signed-rank test for
continuous variables. The Kaplan-Meier method was used to
examine the eﬀect of a change in the number of metastases
on overall survival. For all analyses, probability values <0.05
were considered signiﬁcant, and probability values ranging
from 0.10 to 0.05 were considered trends.
3. Results
3.1. Study Population. One hundred and thirty-three pa-
tients with intracranial metastases were treated with GK-SRS
during the study period. Median patient age was 58.7 years
(range29.0–85.5years).Themajorityofpatientswerefemale
(65%). The most common primary pathology was lung
cancer (47%), followed by breast cancer (20%), melanoma
(11%), and renal cancer (9%). The median time between
pre-GK-SRS and treatment scans was 31 days (range 4–81
days). The median number of metastases identiﬁed on pre-
GK-SRS MRI was 1 (range 1–10); the median number of
metastases identiﬁed on treatment MRI was 2 (range 1–21).
Fifty-twopercentofpatientshadprogressivesystemicdisease
at the time of GK-SRS. Forty-seven percent of patients had
WBRT prior to GK-SRS, 12% of patients had WBRT after
GK-SRS, and 41% of patients did not undergo WBRT at any
0
1
2
3
123
4
5
4+
Number of Pre-GK-SRS Mets
M
e
a
n
“
D
e
l
t
a
M
e
t
s
”
Figure 1: Bar graph demonstrating the relationship between the
number of pre-GK-SRS metastases identiﬁed and the number of
additional metastases (“Delta Mets”) identiﬁed at the time of GK-
SRS. Error bars are shown.
time. Twenty-six percent of patients had cranial surgery and
98% of patients were undergoing chemotherapy (Table 1).
Medianfollow-updurationwas10.4months (range0.3–72.4
months).
3.2. Univariate Analysis. Fifty-four of the 133 patients (41%)
had additional metastases identiﬁed on their treatment scan,
as compared to their initial diagnostic scan. The median
number of additional metastases identiﬁed within this sub-
group was 2 (range 1–11). On univariate analysis, the num-
ber of pre-GK-SRS metastases was predictive of additional
metastases being identiﬁed (P<0.001). Furthermore, the
presence of progressive systemic disease was also predictive
of identifying additional metastases. Speciﬁcally, 65% of
patients who had additional metastases identiﬁed on their
treatment scan had progressive systemic disease at the time
of GK-SRS (P = 0.021). Age, sex, primary pathology, WBRT,
cranial surgery, chemotherapy, and time between scans did
not have a statistically signiﬁcant eﬀect on the identiﬁcation
of additional metastases (Table 1).
3.3. Multivariate Analysis. Based on the results of the uni-
variate analysis, a stepwise multivariate regression analysis
was performed. All predictor variables with P<0.150 were
analyzed and those variables with P<0.100 were included
in the ﬁnal multivariate model. The multivariate analysis
conﬁrmed that both the number of initially identiﬁed (pre-
GK-SRS) lesions (P = 0.001; Figure 1) and the presence
of progressive systemic disease (P = 0.003; Figure 2)w e r e
independently predictive of identifying additional cerebral
metastases. The multivariate analysis also conﬁrmed that the
identiﬁcationofadditionalmetastaseswasindependentofall
other predictor variables analyzed.
3.4. Survival Analysis. To examine the eﬀect of identifying
additional cerebral metastases on survival, the Kaplan-Meier
method was employed. For patients in whom no additional
metastases were identiﬁed, the median survival was 12.1International Journal of Surgical Oncology 3
Table 1: Study population and treatment characteristics∗.
Treatment Study cohort,
n = 133
No additional mets,
n = 79
≥1 additional mets,
n = 54 P
Age, years
Median 58.7 57.5 58.8 0.783
Range 29.0–85.5 29.0–85.5 30.6–82.6
Sex
Male 47 (35) 24 (30) 23 (43) 0.196
Female 86 (65) 55 (70) 31 (57)
Primary pathology
Lung 62 (47) 37 (47) 25 (46) 1.000
Breast 27 (20) 16 (20) 11 (20) 1.000
Melanoma 15 (11) 6 (8) 9 (17) 0.161
Renal 12 (9) 9 (11) 3 (6) 0.359
Other 17 (13) 11 (14) 6 (11) 0.792
WBRT
Pre-GK-SRS 63 (47) 34 (43) 29 (54) 0.289
Post-GK-SRS 16 (12) 9 (11) 7 (13) 0.792
Neither 54 (41) 36 (46) 18 (33) 0.208
Craniotomy
Yes 34 (26) 23 (29) 11 (20) 0.314
No 98 (74) 56 (71) 43 (80)
Chemotherapy
Yes 130 (98) 78 (99) 52 (96) 0.566
No 3 (2) 1 (1) 2 (4)
Time between scans, days 31 (4–81) 29 (4–81) 37 (7–78) 0.111
Number of metastases
Pre-GK-SRS 1 (1–10) 1 (1–9) 2 (1–10) <0.001
GK-SRS 2 (1–21) 1 (1–9) 4 (2–21) <0.001
Progressive systemic disease
Yes 69 (52) 34 (43) 35 (65) 0.021
No 64 (48) 45 (57) 19 (35)
∗Number of patients (%), unless otherwise speciﬁed.
months; however, for patients in whom ≥1 additional
metastases were identiﬁed, the median survival was only
6.9 months (P = 0.021, hazard ratio = 1.56; Figure 3).
Cox multivariate regression analysis revealed that the signif-
icant decrease in survival for patients in whom additional
metastases were identiﬁed is independent of the initial (pre-
GK-SRS) number of metastases identiﬁed (P = 0.024). Of
note, the Kaplan-Meier curves for survival based on presence
of progressive systemic disease are essentially identical to
those obtained from analysis of survival based on additional
metastases (Figure 4). Speciﬁcally, for patients with stable
systemic disease, median survival was 13.8 months, while for
patients with progressive systemic disease, median survival
was 7.0 months (P = 0.012, hazard ratio = 1.63).
4. Discussion
In our retrospective analysis of 133 patients undergoing
GK-SRS for intracranial metastases, we found that 41%
of patients had additional metastases identiﬁed on their
treatment MRI as compared to their diagnostic MRI.
Furthermore, we found that the identiﬁcation of new
metastases correlated with both the number of pre-GK-
SRS metastases identiﬁed and the presence of progressive
systemic disease. Kaplan-Meier analysis revealed a signiﬁcant
decrease in survival for those patients in whom additional
metastases were identiﬁed. Moreover, Kaplan-Meier analysis
also revealed that patients with progressive systemic disease
had similar survival proﬁles to patients in whom additional
cerebral metastases were identiﬁed.
To date, patients undergoing GK-SRS for intracranial
metastases have largely been stratiﬁed into two groups, based
on the number of metastases they harbor. Although the cut-
oﬀ values for these groups have varied (2 versus 3 versus 4
metastases), the literature has been nearly uniform in stat-
ing that those patients who harbor more metastases have
a signiﬁcantly worsened prognosis [1, 3, 8–10]. Moreover,
the number of intracranial metastases present is often used4 International Journal of Surgical Oncology
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Figure 2: Bar graph demonstrating the relationship between pro-
gressive systemic disease and the number of additional metastases
(“Delta Mets”) identiﬁed at the time of GK-SRS. Error bars are
shown.
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Figure 3: Kaplan-Meier plot of overall survival after GK-SRS for
all 133 patients, stratiﬁed by the number of additional metastases
identiﬁed at the time of GK-SRS.
as a surrogate for the aggressiveness of a patient’s systemic
disease, with more intracranial metastases signifying more
aggressive systemic disease [1, 3]. Our results suggest that the
change(orlackthereof)innumberofintracranialmetastases
may be an additional prognostic marker. This data also
implies that for patients in whom additional intracranial
lesions are identiﬁed (on the day of GK-SRS), restaging of
disease or changing systemic therapies may be warranted.
The limitations of this study include the inherent
selection biases present when analyzing a cohort of patients
treated at a single academic medical center. However, our
demographic and clinical patient proﬁles are similar to those
previously reported and we have no reason to believe that
our results are not applicable to all patients with metastatic
intracranial disease. Additionally, precise imaging parame-
ters were not available for the initial diagnostic scans, as
theywerelargelyperformedatoutsideinstitutions.However,
thisheterogeneousassortmentofreferral,diagnosticimaging
scans is likely encountered in the majority of large academic
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Figure 4: Kaplan-Meier plot of overall survival after GK-SRS for
all 133 patients, stratiﬁed by the presence of progressive systemic
disease at the time of GK-SRS.
medical centers, and therefore the results of this study are
likely applicable to institutions similar to ours.
5. Conclusions
This study highlights the dynamic nature of metastatic intra-
cranial disease. Identiﬁcation of additional cerebral metas-
tases on the day of GK-SRS yields important prognostic
information which may be useful in directing patient care.
The ability to perform high-resolution MR imaging, unique
to GK-SRS, facilitates the ability to obtain this prognostic
factor.
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